Drugs /

remetinostat

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
remetinostat
NCI Definition [1]:
A topical formulation containing the histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Upon cutaneous administration, SHP-141 selectively binds to and inhibits HDAC, resulting in an accumulation of highly acetylated histones in the skin (dermis and epidermis), the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes. These events may result in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins. Topical administration of SHP-141 allows for high concentrations of this agent locally while minimizing systemic toxicity.

Clinical Trials

View Clinical Trials for remetinostat

Remetinostat has been investigated in 2 clinical trials, of which 0 are open and 2 are closed. Of the trials investigating remetinostat, 2 are phase 2 (0 open).

Basal cell carcinoma and squamous cell carcinoma are the most common diseases being investigated in remetinostat clinical trials [2].

Drug Details

Synonyms [2]:
shp-141, hdac inhibitor shp-141, shape, remetinostat, methyl 4-((8-(hydroxyamino)-8-oxooctanoyl)oxy)benzoate, methylparaben suberohydroxamic acid phenyl ester
Drug Categories [2]:
Histone deactylase/HDAC inhibitors
Drug Target(s) [2]:
HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
NCIT ID [1]:
C97513

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.